# US 2025/0084038 A1 · Pparg inverse agonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084038 A1
- Document ID: US20250084038A1
- Status: Published application
- Kind: A1
- Application number: 18/664,492
- Filed: 2024-05-15
- Published: 2025-03-13
- Earliest claimed: 2021-11-02
- Assignees: Flare Therapeutics Inc.
- Applicants: Flare Therapeutics Inc.
- Inventors: Jonathan E. Wilson; James E. Audia; Jacob I. Stuckey
- Web page: https://patentgrep.com/patent/US20250084038A1

## CPC

- C07D 215/233: only one oxygen atom which is attached in position 4
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.

## Claims

### Claim 1

A compound having the Formula I:
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halo, (C1-C4)alkyl, or hydroxyl;
X is S, SO, SO2, or —SONH;
R2 is (C1-C4)alkyl, (C1-C4)alkoxy, or halo(C1-C4)alkyl;
R3 is cyano or nitro;
R4 is hydrogen, halo, (C1-C4)alkyl, (C1-C4)alkoxy, or hydroxyl;
R5 is halo, halo (C1-C4)alkyl, or cyano;
R6 is halo, halo (C1-C4)alkyl, (C1-C4)alkyl, or cyano;
R7 is halo, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkyl, halo (C1-C4)alkoxy, —(C1-C4)alkylORa, —(C1-C4)alkylC(O)Ra, —(C1-C4)alkylC(O)ORa, —C(O)NRaRb, —(C1-C4)alkylC(O)NRaRb, —C(O)Ra, —C(O)ORa, —NRaRb, —(C1-C4)alkyINRaRb, —C(O)NRaSO3H, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(S)ORb, —NRCC(O)NaRb, —NRC(S)NRaRb, —NRCS(O)2NRaRb, —C(S)Ra, —S(O)2Ra, —S(O)Ra, —C(S)ORb, —C(S)NRaRb, —NRaC(S)Rb, —SRa, phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein each of said phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl are optionally and independently substituted with 1 to 3 groups selected from R8;
R8 is selected from halo, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4) alkoxy, nitro, oxo, cyano, —(C1-C4)alkylORd, —(C1-C4)alkyIC(O)Rd, —(C1-C4)alkylC(O)ORd, —C(O)NRdRe, —(C1-C4)alkylC(O)NRdRe, —C(O)Rd, —C(O)ORd, —NRdRe, —(C1-C4)alkyINRdRe, —C(O)NRdSO3H, —NRdC(O)Re, —NRdC(O)ORe, —NRfC(S)ORe, —NRfC(O)NdRe, —NRfC(S)NRdRe, —NRfS(O)2NRdRe, —C(S)Rd, —S(O)2Rd, —S(O)Rd, —C(S)ORd, —C(S)NRdRe, —NRdC(S)Re, and —SRd;
Ra, Rb, Rc, Rd, Re, and Rf are each independently hydrogen or (C1-C4)alkyl; and
q and r are each independently 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is of the Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is of the Formula IIa:
or a pharmaceutically acceptable salt thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is of the Formula IIIa:
or a pharmaceutically acceptable salt thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is of the Formula IVa:
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is cyano.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is halo or cyano.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is halo.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R7 is halo, halo (C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, —(C1-C4)alkylORa, —C(O)NRaRb, phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl, wherein each of said phenyl, 4- to 6-membered heterocyclyl, and 5- to 7-membered heteroaryl are optionally and independently substituted with 1 to 3 groups selected from R8.

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R7 is halo, halo (C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy, —(C1-C4)alkylORa, —C(O)NRaRb, phenyl, pyridinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, pyrazolyl, and oxetanyl, wherein each of said phenyl, pyridinyl, pyrazolyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, piperidinyl, and oxetanyl are optionally and independently substituted with 1 to 3 groups selected from R8.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is selected from halo, (C1-C4)alkyl, halo (C1-C4)alkyl, (C1-C4)alkoxy, halo (C1-C4)alkoxy, oxo, and cyano.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is halo (C1-C4)alkyl or (C1-C4)alkyl.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is (C1-C4)alkyl.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is SO2.

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound is of the structural formula:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim at position 29

31-37. (canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 1)

A method of treating a cancer responsive to the suppression of PPARG in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 32

40-66. (canceled)
